10.11.25 -- Best Of September: FDA & CMOT Reports, Cell Line Solutions, And More Top Content This Month

The 2024 Report on the State of Pharmaceutical Quality shows the agency's efforts to normalize post-pandemic oversight under the previous administration.

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

Researchers at Pfizer are developing a cell line that synthesizes these amino acids autonomously, which could reduce costs and increase stability.

Using advanced biophysical techniques, researchers like Miklós Kellermayer have shed light on the dynamic behavior of individual biomolecules, driving breakthroughs in our understanding of life's molecular intricacies.

Discover how to gain precise control over one of the most common and critical forms of protein modification for therapeutic benefit and stability.

Companies still relying on paper-based manufacturing are falling behind. Examine how digital transformation boosts efficiency and reduces errors in this essential shift toward smarter operations.

Accelerating time to market requires moving beyond manual, document-centric methods. Join Emerson’s webinar to explore how digital platforms, standardized modular libraries, and direct connectivity to execution systems streamline process specification and enable rapid flexibility. Learn from real-world examples at a clinical supply center on how digital transfers reduce errors, improve efficiency, and support faster biopharma innovation. Click here to learn more.